Cargando…
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer
The 2003 Leibovich score guides prognostication and selection to adjuvant clinical trials for patients with locally advanced renal cell carcinoma (RCC) after nephrectomy. We provide a robust external validation of the 2003 Leibovich score using contemporary data from SORCE, an international, randomi...
Autores principales: | Oza, Bhavna, Eisen, Tim, Frangou, Eleni, Stewart, Grant D., Bex, Axel, Ritchie, Alastair W.S., Kaplan, Rick, Smith, Benjamin, Davis, Ian D., Stockler, Martin R., Albiges, Laurence, Escudier, Bernard, Larkin, James, Joniau, Steven, Hancock, Barry, Hermann, Gregers G., Bellmunt, Joaquim, Parmar, Mahesh K.B., Royston, Patrick, Meade, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148696/ https://www.ncbi.nlm.nih.gov/pubmed/35213214 http://dx.doi.org/10.1200/JCO.21.01090 |
Ejemplares similares
-
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial
por: Lawrence, Nicola J., et al.
Publicado: (2018) -
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
por: Oza, Bhavna, et al.
Publicado: (2021) -
SORCS1 and SORCS3 control energy balance and orexigenic peptide production
por: Subkhangulova, Aygul, et al.
Publicado: (2018) -
Renal cell carcinoma and the use of sorafenib
por: Larkin, James MG, et al.
Publicado: (2006) -
Impact of Genetic Variation in SORCS1 on Memory Retention
por: Reitz, Christiane, et al.
Publicado: (2011)